Treace Medical Concepts, Inc. ((TMCI)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Treace Medical Concepts, Inc. is conducting a study titled ‘Radiographic and Patient Reported Outcomes Following Combined Adductoplasty™ and Lapiplasty® Procedures for Correction of Metatarsus Adductus and Hallux Valgus (MTA3D)’. The study aims to evaluate the effectiveness of combining Adductoplasty™ and Lapiplasty® procedures in correcting metatarsus adductus and hallux valgus, conditions affecting foot alignment. This research is significant as it could offer improved treatment options for patients suffering from these conditions.
The study tests a device intervention, specifically the Adductoplasty™ and Lapiplasty® procedures, designed to treat patients aged 14 and older with symptomatic metatarsus adductus and hallux valgus. The goal is to assess the outcomes of these combined procedures.
This is an interventional study with a single-group model, focusing on treatment without any masking. The primary purpose is to evaluate the treatment’s effectiveness in a real-world setting.
The study began on October 10, 2022, and is currently recruiting participants. The last update was submitted on May 22, 2025. These dates are crucial as they guide the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Treace Medical Concepts, Inc.’s stock performance by potentially enhancing its product offerings and market position. Investors should watch for updates as successful results could strengthen the company’s competitive edge in the medical device industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.